Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton

Journal of the American Medical Directors Association

Volumn 9, Issue 6, 2008, Pages 439-448

  Locca, Jean François ^a   Büla, Christophe J ^a   Zumbach, Serge ^a   Bugnon, Oliver ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

BPSD; dementia; Nursing homes; pharmaceutical care service; practice recommendations; Switzerland

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMETHIAZOLE; CLOMIPRAMINE; DIAZEPAM; ETOPERIDONE; FLUOXETINE; HALOPERIDOL; LOXAPINE; MAPROTILINE; MELATONIN; MEMANTINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZUCLOPENTHIXOL;

ADMINISTRATIVE PERSONNEL; AGITATION; ALGORITHM; ARTICLE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; COUNSELING; DEMENTIA; DEPRESSION; DISEASE CONTROL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; INSOMNIA; MEDICAL EDUCATION; MENTAL DISEASE; NURSING HOME; PHARMACEUTICAL CARE; PHARMACIST; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; QT PROLONGATION; SEDATION; SIDE EFFECT; SWITZERLAND; SYMPTOM; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; DEMENTIA; FEMALE; HOMES FOR THE AGED; HUMANS; MALE; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; NURSING HOMES; PRACTICE GUIDELINES AS TOPIC; SWITZERLAND;

EID: 45549099830     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2008.04.003     Document Type: Article

References (50)

1. Höpflinger F., and Hugentobler V. Soins familiaux, ambulatoires et stationnaires des personnes âgées en Suisse - Observations et perspectives (2006), Médecine et Hygiène, Chêne-Bourg
2. Guignard E., and Bugnon O. Pharmaceutical care in community pharmacies: Practice and research in Switzerland. Ann Pharmacother 40 3 (2006) 512-517
3. Matthews F.E., and Dening T. Prevalence of dementia in institutional care. Lancet 360 9328 (2002) 225-226
4. Lyketsos C.G., Lopez O., Jones B., et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288 12 (2002) 1475-1483
5. Lyketsos C.G. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr 19 3 (2007) 409-420
6. Buhr G.T., and White H.K. Difficult behaviors in long-term care patients with dementia. J Am Med Dir Assoc 8 (2007) 101-113
7. Tunis S.L., Edell W.S., Adams B.E., and Kennedy J.S. Characterizing behavioral and psychological symptoms of dementia (BPSD) among geropsychiatric inpatients. J Am Med Dir Assoc 3 (2002) 146-151
8. Gobert M., and D'hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry 20 (2005) 712-721
9. Ballard C., and Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD003476
10. Lonergan E., Luxenberg J., and Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2 (2002) CD002852
11. Jansen S.L., Forbes D.A., Duncan V., et al. Melatonin for cognitive impairment. Cochrane Database Syst Rev 1 (2006) CD003802
12. Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with dementia: A national clinical guideline (2006), Scottish Intercollegiate Guidelines Network, Edinburgh. www.sign.ac.uk Accessed December 12, 2007
13. Bains J., Birks J.S., and Dening T.R. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 4 (2002) CD003944
14. National Institute for Health and Clinical Excellence (NICE). Guidance on Dementia: Supporting people with dementia and their careers in health and social care (2006), National Institute for Clinical Health and Excellence, London. www.nice.org.uk Accessed December 12, 2007
15. Lonergan E.T., Cameron M., and Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2 (2004) CD003945
16. Kirchner V., Kelly C.A., and Harvey R.J. Thioridazine for dementia. Cochrane Database Syst Rev 3 (2001) CD000464
17. Martinon-Torres G., Fioravanti M., and Grimley E.J. Trazodone for agitation in dementia. Cochrane Database Syst Rev 4 (2004) CD004990
18. Shekelle P., Maglione M., Bagley S., et al. Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Comparative Effectiveness Review No. 6 (2007), Agency for Healthcare Research and Quality, Rockville, MD. January www.effectivehealthcare.ahrq.gov/reports/final.cfm Accessed December 12, 2007
19. Lyketsos C.G., Colenda C.C., Beck C., et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 14 7 (2006) 561-572
20. International Psychogeriatric Association (IPA). Behavioral and Psychological Symptoms of Dementia (BPSD) Educational Pack - Module 6. International Psychogeriatric Association, 1997. www.ipa-online.org Accessed December 12, 2007
21. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry 154 5 Suppl (1997) 1-39
22. American Geriatrics Society, American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in U.S. nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 51 9 (2003) 1287-1298
23. Alexopoulos G.S., Streim J., Carpenter D., et al. Using antipsychotic agents in older patients. J Clin Psychiatry 65 Suppl 2 (2004) 5-99
24. Alexopoulos G.S., Jeste D.V., Chung H., et al. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: Methods, commentary, and summary. Postgrad Med Spec No (2005) 6-22
25. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 5 (2005) 596-608
26. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 9 4 (2001) 361-381
27. Peskind E.R. Management of depression in long-term care of patients with Alzheimer's disease. J Am Med Dir Assoc 4 6 Suppl (2003) S141-S145
28. National Institute for Health and Clinical Excellence (NICE) Guidance on Depression. Management of depression in primary and secondary care (2004), National Institute for Clinical Health and Excellence, London. www.nice.org.uk Accessed December 12, 2007
29. Kallenbach L.E., and Rigler S.K. Identification and management of depression in nursing facility residents. J Am Med Dir Assoc 7 7 (2006) 448-455
30. Lonergan E., Britton A.M., Luxenberg J., et al. Antipsychotics for delirium. Cochrane Database Syst Rev 2 (2007) CD005594
31. Wild R., Pettit T., and Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 3 (2003) CD003672
32. Mosimann U.P., and McKeith I.G. Dementia with Lewy bodies-diagnosis and treatment. Swiss Med Wkly 133 (2003) 131-142
33. McKeith I., Del S.T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
34. Beier M.T. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly. Am J Health Syst Pharm 64 (2007) S9-S17
35. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
36. Waldemar G., Dubois B., Emre M., et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14 1 (2007) e1-e26
37. Lawlor B.A. Behavioral and psychological symptoms in dementia: The role of atypical antipsychotics. J Clin Psychiatry 65 (2004) 5-10
38. Liperoti R., Mor V., Lapane K.L., et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 64 9 (2003) 1106-1112
39. Howard R.J., Juszczak E., Ballard C.G., et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357 (2007) 1382-1392
40. Ballard C., and Howard R. Neuroleptic drugs in dementia: Benefits and harm. Nat Rev Neurosci 7 (2006) 492-500
41. Johnson F., and Stevens T. Pharmacological interventions for sleep disorder in people with dementia (Protocol). Cochrane Database Syst Rev (2001) October. CD003258
42. McCurry S.M., Gibbons L.E., Logsdon R.G., et al. Nighttime insomnia treatment and education for Alzheimer's disease: A randomized, controlled trial. J Am Geriatr Soc 53 (2005) 793-802
43. Ather S.A., Shaw S.H., and Stoker M.J. A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly. Acta Psychiatr Scand Suppl 329 (1986) 81-91
44. Dehlin O. Hypnotic effect of chlormethiazole in geriatric patients during long-term treatment. Acta Psychiatr Scand Suppl 329 (1986) 112-115
45. Fetveit A., and Bjorvatn B. Bright-light treatment reduces actigraphic-measured daytime sleep in nursing home patients with dementia: A pilot study. Am J Geriatr Psychiatry 13 5 (2005) 420-423
46. Gill S.S., Bronskill S.E., Normand S.L., et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146 11 (2007) 775-786
47. Rochon P.A., Stukel T.A., Bronskill S.E., et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 167 (2007) 676-683
48. Schneeweiss S., Setoguchi S., Brookhart A., et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 176 5 (2007) 627-632
49. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294 15 (2005) 1934-1943
50. Holmes C., Wilkinson D., Dean C., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63 2 (2004) 214-219